Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Here's a technical look at how to trade some of the most active stocks on the market right now.
The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.